In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models

Molecular Cancer Therapeutics

Volumn 8, Issue 1, 2009, Pages 75-82

  Kolinsky, Kenneth ^a   Shen, Ben Quan ^d   Zhang, Yu E ^b   Kohles, Joseph ^c   Dugan, Ute ^c,e   Zioncheck, Thomas F ^d   Heimbrook, David ^a   Packman, Kathryn ^a   Higgins, Brian ^a,c  

^a Discovery Oncology   (United States)

^b Pharmaceutical and Analytical R and D   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d GENENTECH INC   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; OXALIPLATIN; THYMIDINE PHOSPHORYLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL STRAIN HT29; COLORECTAL CANCER; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIFESPAN; MONOTHERAPY; MOUSE; NATIONAL CANCER INSTITUTE CRITERIA; NATIONAL HEALTH ORGANIZATION; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SCORING SYSTEM; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG TOLERANCE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; MICE; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149521889     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0596     Document Type: Article

References (40)

1. Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 2007;8:898-911.
2. Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998;55:1091-7.
3. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-81.
4. Schüller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45:291-7.
5. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998;58:685-90.
6. Ishitsuka H. Capecitabine: preclinical pharmacology studies. Invest New Drugs 2000;18:343-54.
7. Ninomiya I, Terada I, Yoshizumi T, et al. Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum. Int J Cancer 2004;112:135-42.
8. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-106.
9. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-92.
10. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704.
11. Díaz-Rubio E, Tabernero J, Gomez-Espana A, et al. Phase III study of capecitabine plus oxaliplatin (XELOX) versus continuous infusion 5-fluorouracil plus oxaliplatin (FUOX) as first-line therapy in metastatic colorectal cancer: final report of the Spanish TTD Cooperative Group trial. J Clin Oncol 2007;25:4224-30.
12. Thomas R, Quinn M, Wilson R, et al. A phase I trial of capecitabine (CAPE) and oxaliplatin (OHP). Proc Am Soc Clin Oncol 2001;20:(abstr 530).
13. Tabernero J, Butts CA, Cassidy J, et al. Capecitabine and oxaliplatin in combination (Xelox) as first line therapy for patients (pts) with metastatic colorectal cancer (MCRC): results of an international multicenter phase II trial. Proc Am Soc Clin Oncol 2002;21:(abstr 531).
14. Rothenberg ML, Navarro M, Butts C, et al. Phase III trial of capecitabine + oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer (MCRC). J Clin Oncol 2007;25(suppl 18S):(abstr 4031).
15. Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX compared to FOLFOX4: survival and response results from XELOX-1/NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC). J Clin Oncol 2007;25(suppl 18S):(abstr 4030).
16. Saltz L, Clarke S, Diaz-Rub i o E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. J Clin Oncol 2007;25(suppl 18S):(abstr 4028).
17. Tol J, Koopman M, Rodenburg CJ, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008;19:734-8.
18. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-80.
19. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95:1789-97.
20. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
21. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumabin combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44.
22. Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000;18:1337-45.
23. Traina TA, Theodoulou M, Higgins B, et al. In vivo activity of a novel regimen of capecitabine in a breast cancer xenograft model. Breast Cancer Res Treat 2006;100(suppl 1, S279):(abstr 6071).
24. Norton L, Dugan U, Young D, et al. Optimizing chemotherapeutic dose-schedule (CDS) by Norton-Simon modeling: capecitabine (Xeloda = X). Proc Am Assoc Cancer Res, 96th Annual Meeting April 16-20, 2005 (abstr 5007).
25. Higgins B, Kolinsky K, Linn M, et al. Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model. Anticancer Res 2007;27:2279-87.
26. Nishimura G, Terada I, Kobayashi T, et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep 2002;9:479-82.
27. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013-9.
28. Luccioni C, Beaumatin J, Bardot V, Lefrançois D. Pyrimidine nucleotide metabolism in human colon carcinomas: comparison of normal tissues, primary tumors and xenografts. Int J Cancer 1994;58:517-22.
29. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84:1424-31.
30. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
31. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007;67:2729-35.
32. Sawada N, Kondoh K, Mori K. Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts. Oncol Rep 2007;18:775-8.
33. Brennan B, Siu L, Dhesy-Thind B, et al. Pharmacokinetic (PK) interactions between capecitabine (X), oxaliplatin (O) and bevacizumab (A) when used in combination for first-line treatment of metastatic colorectal cancer (MCRC). J Clin Oncol 2007;25:(suppl 18S):(abstr 2554).
34. Scheithauer W, Kornek GV, Raderer M, et al. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer. Ann Oncol 2002;13:1583-9.
35. Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003;21:1307-12.
36. Traina TA, Theodoulou M, Feigin K, et al. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol 2008;26:1797-802.
37. Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008;26:2118-23.
38. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. J Clin Oncol 2006;24(suppl 148s):(abstr 3510).
39. Bennouna J, Ducreux M, Hebbar M, et al. Preliminary efficacy findings from a randomized phase III study of capecitabine + oxaliplatin (XELOX) vs. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first line treatment for metastatic colorectal cancer (MCRC). Gastrointestinal Cancer Symposium 2007;(abstr 272).
40. Porschen R, Arkenau HT, Kubicka S, et al. Capecitabine plus oxaliplatin versus 5-fluorouracil/leucovorin plus oxaliplatin: a randomized comparison in metastatic colorectal cancer. J Clin Oncol 2007;25:4217-23.